A significant Scandinavian examine by Karolinska Institutet reveals that GLP-1 analogs, utilized in diabetes and weight problems remedy, don’t improve thyroid most cancers threat, confirming their security over practically 4 years of statement.
A complete examine by Karolinska Institutet discovered no proof that GLP-1 analogs improve the chance of thyroid most cancers. Analyzing knowledge from over 435,000 sufferers throughout Scandinavia, the examine in contrast GLP-1 customers to these on different diabetes therapies over practically 4 years, persistently exhibiting no elevated most cancers threat. This analysis is a part of a broader investigation into the real-world results of newer diabetes drugs.
GLP-1 analogs, medicine extensively used for treating diabetes and weight problems, have raised considerations about doubtlessly rising thyroid most cancers threat. Nevertheless, a complete Scandinavian examine carried out by researchers from Karolinska Institutet has discovered no proof supporting this connection. The findings are printed in The BMJ.
GLP-1 receptor agonists, also called GLP-1 analogs, cut back blood sugar ranges and urge for food. They’re extensively used within the remedy of kind 2 diabetes and weight problems, with their medical use steadily rising. Earlier research and antagonistic occasion knowledge have prompt that these medicine may very well be related to an elevated threat of thyroid tumors. Nevertheless, because of limitations in knowledge and methodology, clear conclusions couldn’t be drawn, resulting in uncertainty about this potential aspect impact.
“Many individuals take these medicines, so it is very important examine potential dangers related to them,” says Björn Pasternak, principal researcher on the Division of Drugs, Solna, at Karolinska Institutet in Sweden. “Our examine covers a broad group of sufferers and offers robust help that GLP-1 analogs usually are not related to an elevated threat of thyroid most cancers.”
Comparative Threat Evaluation
The researchers analyzed nationwide register knowledge from Denmark, Norway, and Sweden of about 145,000 sufferers handled with GLP-1 analogs, primarily liraglutide or semaglutide, and 290,000 sufferers handled with one other diabetes drug (DPP4 inhibitors). The chance of thyroid most cancers was in contrast between the teams over a mean follow-up interval of just below 4 years.
GLP-1 remedy was not related to an elevated threat of thyroid most cancers. The outcomes have been constant additionally when in comparison with a 3rd diabetes remedy group (SGLT2 inhibitors).
“We can not rule out that the chance of sure subtypes of thyroid most cancers is elevated in smaller affected person teams that we couldn’t examine right here, for instance in folks with a excessive congenital threat of medullary thyroid most cancers who’re suggested towards utilizing these medicine,” says Peter Ueda, assistant professor on the Division of Drugs, Solna, at Karolinska Institutet.
The continued analysis program at Karolinska Institutet investigates the consequences and potential negative effects of newer diabetes drugs reminiscent of GLP-1 analogs and SGLT2 inhibitors. These drugs are actually getting used to deal with broader affected person teams, together with these with weight problems, coronary heart failure, and kidney failure.
“We all know from randomized medical trials that they’ve constructive results, however the medical actuality is totally different with sufferers various in illness severity, comorbidities, and adherence to remedy suggestions,” says Björn Pasternak. “It’s subsequently important to research how these medicines carry out in on a regular basis medical settings.”
Reference: “Glucagon-like peptide 1 receptor agonist use and threat of thyroid most cancers: Scandinavian cohort examine” by Björn Pasternak, Viktor Wintzell, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Christian Jonasson, Kristian Hveem, Henrik Svanström, Mads Melbye and Peter Ueda, 10 April 2024, BMJ.
DOI: 10.1136/bmj-2023-078225
The analysis was primarily financed by the Swedish Most cancers Society, the Swedish Analysis Council, and Karolinska Institutet. One of many co-authors is an worker of NordicRWE and one other co-author stories charges for counseling and lectures from a number of pharmaceutical corporations, see the scientific article for extra details about potential conflicts of curiosity.
